Literature DB >> 2125835

Efficacy of encainide in supraventricular arrhythmias.

P E Pool1.   

Abstract

This review summarizes the data from all the studies conducted in the United States and Europe that have evaluated the efficacy of encainide in patients with a variety of supraventricular arrhythmias. Using clinical criteria of efficacy, encainide was found to be effective or partially effective in 77% of patients evaluated by electrophysiologic means. Similar levels of efficacy were observed in patients with AV as well as AV nodal reentry arrhythmias. Patients with other forms of supraventricular arrhythmias in smaller series also experienced comparable degrees of efficacy. Encainide was discontinued because of intolerance by 8% of the patients in these studies: 6% because of side effects and 2% because of proarrhythmia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125835     DOI: 10.1007/bf00357033

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide.

Authors:  P E Pool; B D Quart
Journal:  Am J Cardiol       Date:  1988-12-20       Impact factor: 2.778

2.  Comparison of encainide and quinidine for supraventricular tachyarrhythmias.

Authors:  P J Mäkynen; P J Koskinen; T E Saaristo; R K Liisanantti
Journal:  Am J Cardiol       Date:  1988-12-20       Impact factor: 2.778

3.  Long-term follow-up of incessant supraventricular tachycardia treated with oral encainide.

Authors:  P Brugada; H J Wellens
Journal:  Eur Heart J       Date:  1987-04       Impact factor: 29.983

4.  Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry.

Authors:  W M Miles; M S Chang; J J Heger; R L Rinkenberger; D P Zipes; E N Prystowsky
Journal:  Am Heart J       Date:  1987-07       Impact factor: 4.749

5.  Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation.

Authors:  M Chimienti; M Moizi; J A Salerno; C Klersy; L Guasti; M Previtali; E Marangoni; C Montemartini; P Bobba
Journal:  Eur Heart J       Date:  1987-03       Impact factor: 29.983

6.  Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.

Authors:  H Abdollah; P Brugada; M Green; M Wehr; H J Wellens
Journal:  Am J Cardiol       Date:  1984-09-01       Impact factor: 2.778

7.  The use of encainide in atrial fibrillation.

Authors:  S C Vlay; P R Reid
Journal:  Clin Cardiol       Date:  1984-09       Impact factor: 2.882

8.  Encainide for resistant supraventricular tachycardia in children: follow-up report.

Authors:  J F Strasburger; R T Smith; J P Moak; C Gothing; A Garson
Journal:  Am J Cardiol       Date:  1988-12-20       Impact factor: 2.778

9.  Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia.

Authors:  G V Naccarelli; W M Jackman; M Akhtar; R L Rinkenberger; K J Friday; A H Dougherty; P Tchou; J A Yeung-Lai-Wah
Journal:  Am J Cardiol       Date:  1988-12-20       Impact factor: 2.778

10.  Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.

Authors:  K H Kuck; K P Kunze; M Schlüter; W Duckeck
Journal:  Am J Cardiol       Date:  1988-12-20       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.